SI2419086T1 - Biološko sprejemljivi sestavki amorfne alfa-(N-sulfonamid)acetamidne spojine - Google Patents

Biološko sprejemljivi sestavki amorfne alfa-(N-sulfonamid)acetamidne spojine

Info

Publication number
SI2419086T1
SI2419086T1 SI201030355T SI201030355T SI2419086T1 SI 2419086 T1 SI2419086 T1 SI 2419086T1 SI 201030355 T SI201030355 T SI 201030355T SI 201030355 T SI201030355 T SI 201030355T SI 2419086 T1 SI2419086 T1 SI 2419086T1
Authority
SI
Slovenia
Prior art keywords
sulfonamido
acetamide compound
amorphous alpha
bioavailable compositions
bioavailable
Prior art date
Application number
SI201030355T
Other languages
English (en)
Inventor
Ruiling F. Hartley
Raja M. Haddadin
Feng Qian
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SI2419086T1 publication Critical patent/SI2419086T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI201030355T 2009-04-14 2010-04-12 Biološko sprejemljivi sestavki amorfne alfa-(N-sulfonamid)acetamidne spojine SI2419086T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16906609P 2009-04-14 2009-04-14
PCT/US2010/030679 WO2010120662A2 (en) 2009-04-14 2010-04-12 Bioavailable compositions of amorphous alpha-(n-sulfonamido)acetamide compound
EP10714413.1A EP2419086B1 (en) 2009-04-14 2010-04-12 Bioavailable compositions of amorphous alpha-(n-sulfonamido)acetamide compound

Publications (1)

Publication Number Publication Date
SI2419086T1 true SI2419086T1 (sl) 2013-10-30

Family

ID=42664672

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201030355T SI2419086T1 (sl) 2009-04-14 2010-04-12 Biološko sprejemljivi sestavki amorfne alfa-(N-sulfonamid)acetamidne spojine

Country Status (21)

Country Link
US (1) US20100261768A1 (sl)
EP (1) EP2419086B1 (sl)
JP (1) JP2012524090A (sl)
KR (1) KR20120027142A (sl)
CN (1) CN102387788B (sl)
AR (1) AR076306A1 (sl)
AU (1) AU2010236701A1 (sl)
BR (1) BRPI1012523A2 (sl)
CA (1) CA2758709A1 (sl)
DK (1) DK2419086T3 (sl)
EA (1) EA201171207A1 (sl)
ES (1) ES2426403T3 (sl)
HR (1) HRP20130807T1 (sl)
MX (1) MX2011010513A (sl)
NZ (1) NZ595411A (sl)
PL (1) PL2419086T3 (sl)
PT (1) PT2419086E (sl)
SI (1) SI2419086T1 (sl)
SM (1) SMT201300106B (sl)
TW (1) TW201043269A (sl)
WO (1) WO2010120662A2 (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162498A0 (en) 2001-12-20 2005-11-20 Bristol Myers Squibb Co (N-sulphonamido) acetamide derivatives and pharmaceutical compositions containing the same
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US9095585B2 (en) * 2011-07-21 2015-08-04 Bristol-Myers Squibb Company Bioavailable compositions of amorphous piperidinyl compounds
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3999007A (en) * 1975-10-09 1976-12-21 Carl Joseph Crane Aircraft visual approach/landing reproducer device and system
US5136301A (en) * 1989-08-30 1992-08-04 Rockwell International Corporation Primary flight display system having a vertical linear altimeter
US5274094A (en) * 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) * 1992-02-11 1992-03-25 British Bio Technology Compounds
EP0750238B1 (en) * 1995-06-20 2000-03-01 Honeywell Inc. Integrated ground collision avoidance system
IL123901A (en) * 1995-11-17 2003-06-24 Warner Lambert Co Sulfonamide inhibitors of matrix metalloproteinases and pharmaceutical compositions comprising them
US6233522B1 (en) * 1998-07-06 2001-05-15 Alliedsignal Inc. Aircraft position validation using radar and digital terrain elevation database
US6313123B1 (en) * 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6570531B1 (en) * 2000-04-27 2003-05-27 Rockwell Collins, Inc. Satellite navigation receiver designed for compatibility with aircraft automatic landing systems
US6483454B1 (en) * 2000-11-28 2002-11-19 Bae Systems Aerospace Inc. Close formation aircraft collision avoidance
IL162498A0 (en) * 2001-12-20 2005-11-20 Bristol Myers Squibb Co (N-sulphonamido) acetamide derivatives and pharmaceutical compositions containing the same
TWI336698B (en) * 2003-03-31 2011-02-01 Wyeth Corp Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
FR2870605B1 (fr) * 2004-05-18 2010-10-08 Airbus France Procede et dispositif de guidage automatique d'un aeronef, pour un vol au moins en partie a basse altitude
FR2880456B1 (fr) * 2005-01-03 2007-02-23 Airbus France Sas Procede et dispositif d'alerte sonore lors de la desactivation d'un pilote automatique d'un aeronef
FR2886439B1 (fr) * 2005-05-24 2010-11-05 Eurocopter France Procede et dispositif d'aide au pilotage d'un aeronef a basse altitude
KR101374928B1 (ko) * 2005-11-09 2014-03-14 노파르티스 아게 일시적 가소제를 사용한 약학 조성물의 제조 방법
FR2897448B1 (fr) * 2006-02-14 2008-03-14 Airbus France Sas Procede et systeme d'aide au pilotage d'un aeronef.
KR20080093126A (ko) * 2006-02-17 2008-10-20 와이어쓰 술폰아미드 치환된 알코올 및 이의 중간체의 제조 방법
RU2008131051A (ru) * 2006-02-17 2010-03-27 Вайет (Us) Избирательное n-сульфонилирование 2-амино трифторалкильнзамещенных спиртов
RS20090406A (en) * 2006-03-20 2010-12-31 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
WO2007109604A2 (en) * 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
FR2911988B1 (fr) * 2007-01-26 2016-03-25 Airbus France Procede et dispositif pour determiner une hauteur maximale de stabilisation lors de la phase finale de vol d'un avion
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Also Published As

Publication number Publication date
TW201043269A (en) 2010-12-16
DK2419086T3 (da) 2013-09-30
JP2012524090A (ja) 2012-10-11
MX2011010513A (es) 2011-11-29
CN102387788A (zh) 2012-03-21
PL2419086T3 (pl) 2013-11-29
EP2419086A2 (en) 2012-02-22
AR076306A1 (es) 2011-06-01
AU2010236701A1 (en) 2011-10-20
CN102387788B (zh) 2013-07-10
EP2419086B1 (en) 2013-06-26
WO2010120662A3 (en) 2011-09-15
ES2426403T3 (es) 2013-10-23
SMT201300106B (it) 2013-11-08
NZ595411A (en) 2013-02-22
WO2010120662A2 (en) 2010-10-21
EA201171207A1 (ru) 2012-03-30
CA2758709A1 (en) 2010-10-21
US20100261768A1 (en) 2010-10-14
PT2419086E (pt) 2013-09-04
HRP20130807T1 (hr) 2013-09-30
BRPI1012523A2 (pt) 2016-03-29
KR20120027142A (ko) 2012-03-21

Similar Documents

Publication Publication Date Title
HRP20130807T1 (hr) Bioraspoloživi sastavi tvari amorfnog alfa-(n-sulfonamido)acetamida
HK1254977A1 (zh) 索非布韋(sofosbuvir)的結晶形式
IL248056B (en) Compounds of polymeric myrcene
HK1155161A1 (en) Novel intermediates useful for preparing alpha-(n-sulfonamido)acetamide compound
IL210322A (en) A crystalline form of sitagliptin malate
EP2427999A4 (en) Sanitization of packets
PL2280916T3 (pl) Kompozycje chlorofluorowodoroolefin
GB0906281D0 (en) Detergent compositions
PL2340960T3 (pl) Przedział stanu naładowania
EP2473042A4 (en) METHODS AND COMPOSITIONS FOR DESTROYING BIOFILM USING COMPOUNDS DERIVED FROM CHITOSAN
EP2477628A4 (en) PREPARATION OF CRYSTALLINE FORMS OF DIHYDROPYRAZOLOPYRIMIDINONE
IL264118A (en) Pharmaceutical preparation of amorphous acyl sulfonamide
EP2376561A4 (en) AMORPHIC MICROPOROUS ORGANOSILICATE COMPOSITIONS
ZA201106206B (en) A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
ZA201202097B (en) Crystalline forms of substituted pyrazolopyrimidines
ZA201109045B (en) Crystalline form of pemirolast
EP2512247A4 (en) NOVEL THIOPHEN INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE
ZA201007397B (en) Delayed release compositions of duloxetine
ZA201004762B (en) Crystalline form of abacavir that is essentially free of solvent
IL206021A0 (en) Crystalline form of azelastine
TWM371616U (en) Improved mechanism for adjusting torque of wrench
PL2408799T3 (pl) Nowa krystaliczna postać anty-progesteronu CDB-4124
HUP0800755A2 (en) Crystalline forms of rosiglitazone
IL209326A0 (en) Solid state forms of aliskiren compounds
GB0908549D0 (en) Meloxicam compositions